• PDF / 169,128 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 45 Downloads / 200 Views

DOWNLOAD

REPORT

---

1 S

Pneumocystis pneumonia and thrombocytopenic bleed: 2 case reports In a retrospective study of 462 patients conduced at Moffitt Cancer Center, USA from January 2008 to June 2019, two patients were described, who developed Pneumocystis carinii pneumonia (PCP) or thrombocytopenic bleed during treatment with capecitabine and temozolomide [routes, dosages, duration of treatment to reaction onset and outcomes not stated] for neuroendocrine neoplasms. The patients with neuroendocrine neoplasms started receiving capecitabine and temozolomide. Subsequently, one patient developed PCP, and another patient developed thrombocytopenic bleed. The patient, who had developed thrombocytopenic bleed, died two months after the development of thrombocytopenic bleed [cause of death not stated]. Al-Toubah TE, et al. Toxicity analysis of capecitabine/temozolomide in NETs. Journal of Clinical Oncology 38 (Suppl.): 4614, No. 15, 20 May 2020. Available from: URL: 803502880 http://doi.org/10.1200/JCO.2020.38.15_suppl.4614 [abstract]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823